Diverse Psychotomimetics Act Through a Common Signaling Pathway

@article{Svenningsson2003DiversePA,
  title={Diverse Psychotomimetics Act Through a Common Signaling Pathway},
  author={Per Svenningsson and Eleni T. Tzavara and Robert J. Carruthers and Ilan Rachleff and Sigrid Wattler and Michael Nehls and David McKinzie and Allen A. Fienberg and G. Nomikos and Paul Greengard},
  journal={Science},
  year={2003},
  volume={302},
  pages={1412 - 1415}
}
Three distinct classes of drugs: dopaminergic agonists (such as D-amphetamine), serotonergic agonists (such as LSD), and glutamatergic antagonists (such as PCP) all induce psychotomimetic states in experimental animals that closely resemble schizophrenia symptoms in humans. Here we implicate a common signaling pathway in mediating these effects. In this pathway, dopamine- and an adenosine 3′,5′-monophosphate (cAMP)–regulated phospho-protein of 32 kilodaltons (DARPP-32) is phosphorylated or… 

GSK-3β activity and hyperdopamine-dependent behaviors

Haloperidol-induced immediate early genes in striatopallidal neurons requires the converging action of cAMP/PKA/DARPP-32 and mTOR pathways

This work focused on the cell type-specific (D2R-MSNs) regulation of some striatal immediate early genes (IEGs) and found that haloperidol-induced IEGs in the striatum required the synergistic activation of A2a (adenosine) and NMDA (glutamate) receptors.

The psychotomimetic effects of PCP , LSD and MDMA : Pharmacological models of schizophrenia ?

The primary question addressed herein, whether PCP-induced psychosis is a valid model of schizophrenia, gives rise to additional questions about the validity of ketamine challenge at subanaesthetic doses in humans as a model of PCP psychosis, and in turn, questions aboutThe validity of drug-induced changes in non-human animals (rodents, monkeys) treated with PCP and its analogues (ketamine or dizocilpine [MK-801]) as models of PCPs psychosis.

DARPP-32 mediates the actions of multiple drugs of abuse

There is now alarge body of evidence that supports a key role for DARPP-32-dependent signaling in mediating the actions of multiple drugs of abuse including cocaine, amphetamine, nicotine, caffeine, LSD, PCP, ethanol and morphine.

Inhibition of glycogen synthase kinase-3 attenuates psychotomimetic effects of ketamine

A phosphatase cascade by which rewarding stimuli control nucleosomal response

It is shown that drugs of abuse, as well as food reinforcement learning, promote the nuclear accumulation of 32-kDa dopamine-regulated and cyclic-AMP-regulated phosphoprotein (DARPP-32), a potent inhibitor of protein phosphatase-1 and increases the phosphorylation of histone H3, an important component of nucleosomal response.

Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways.

Recent advances in understanding hallucinogen drug action are reviewed through characterization of structure, neuroanatomical location, and function of the 5-HT2A receptor.

The Akt-GSK-3 signaling cascade in the actions of dopamine.

...

References

SHOWING 1-10 OF 18 REFERENCES

Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research.

The data demonstrate that the neuronal substrate of normal and abnormal thought and behavior is associated with a distributed neuronal network and with multiple interactive neurotransmitter systems, and support the view that the hallucinogen challenge paradigm constitutes a powerful tool for elucidating the pathophysiology of neuropsychiatric disorders.

DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1

The basal ganglia of mammalian brain contain a region-specific neuronal phosphoprotein that is a protein phosphatase inhibitor, and like inhibitor-110, DARPP-32 is effective as an inhibitor in its phosphorylated but not its dephosphorylated form.

Mood stabilizers, glycogen synthase kinase-3β and cell survival

Substantial evidence now indicates that an important property of the mood stabilizer, lithium, is to influence GSK3β-linked signaling pathways, which raises the possibility that other mood stabilizers act in a similar manner, which may include modulation of signaling systems leading to GSK1β, direct regulation of GSK2β or regulation of signaling intermediates downstream of G SK3β.

Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons

Dopamine and cyclic AMP-regulated phospho-protein DARPP-32 is a bifunctional signal transduction molecule which, by distinct mechanisms, controls a serine/threonine kinase and aserine/Threonine phosphatase.

Study of a new schizophrenomimetic drug; sernyl.

Introduction The production of model psychoses has been employed as a technique for testing hypotheses relevant to the causes, correlates, and treatment of schizophrenia since 1921, when De Jong

Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence.

A precise identification of neurotransmitter aberrations in schizophrenia will probably provide clues for a better understanding of the disease and for the development of new treatment and prevention strategies.

Subchronic Treatment with Haloperidol and Clozapine in Rats with Neonatal Excitotoxic Hippocampal Damage

The results indicate that the two neuroleptics exerted differential behavioral effects in neurologically intact and hippocampally lesioned animals, and that these effects were also drug-specific.

Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.

In this new cohort of subjects the authors replicated their initial observation of a dysregulation of striatal dopamine release in schizophrenia, with a significantly larger reduction in D2 receptor availability following acute amphetamine challenge than the comparison group.

Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines.

  • S. Snyder
  • Psychology, Medicine
    The American journal of psychiatry
  • 1973
The author discusses some implications of the roles dopamine and norepinephrine may play in mediating some schizophrenic symptoms.